CBP501 Phase 1b data published at ASCO
|Granted CBS9106 global license to Stemline Therapeutics, Inc.|
|Initiated CBP501 Phase 1b clinical study(dose finding cohort) with CDDP and nivolumab combination in the US.|
|IDO/TDO Joint Research Agreement with University of Shizuoka|
|Joint Research (screening) Agreement with Fuji Pharma Valley Project.|
|Stemline initiated CBS9106 (SL-801) Phase 1 study for solid tumors.|
|Joint Research (Drug Efficacy) Agreement with The University of Tokyo Hospital, utilizing their proprietary pancreatic cancer model mouse.|
|Granted CBS9106 license (except for Japan, China, Taiwan and South Korea) to Stemline.|
Published preliminary data from CBP501 Phase 2 clinical study in patients with Non Small Cell Lung Cancer(“NSCLC”).
CBP501 achieve the primary endpoint of the Phase 2 clinical study in patients with Malignant Pleural Mesothelioma(“MPM”)
|CBP501 received orphan drug designation from FDA for MPM.|
|Terminated CBP501 Joint Development Agreement with Takeda Pharmaceutical Co., Ltd.|
Went public on the Tokyo Stock Exchange Mothers Market.
|Initiated CBP501 Phase 2 clinical study in patients with MPM in three drug combinations with Cisplatin and Pemetrexed in the US.|
|Initiated CBP501 Phase 1 clinical study in three drug combinations with Cisplatin and Pemetrexed in the US.|
|Entered into CBP501 Joint Development Agreement with Takeda.|
Initiated CBP501 Phase 1 clinical study in two drug combinations with Cisplatin in the US.
|Initiated CBP501 single-drug Phase 1 clinical study in the US.|
|Set up the Laboratory in Numazu, Shizuoka.|
|Established CanBas Co., Ltd. in Toyota, Aichi.|